Enzalutamide in Metastatic Prostate Cancer before ChemotherapyTomasz M. Beer, Bertrand Tombal, Andrew J. Armstrong et al.|New England Journal of Medicine|2014Cited by 3k
Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyCharles J. Ryan, Dana E. Rathkopf, Matthew R. Smith et al.|New England Journal of Medicine|2012Cited by 2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Howard I. Scher, Andrew J. Armstrong, Michael J. Morris et al.|Journal of Clinical Oncology|2016Cited by 1.6k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyCharles J. Ryan, Dana E. Rathkopf, Matthew R. Smith et al.|The Lancet Oncology|2015Cited by 1.4k
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyHoward I. Scher, Charles L. Sawyers, Tomasz M. Beer et al.|The Lancet|2010Cited by 1.1k